We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$868M
AUM Growth
+$59.7M
Cap. Flow
+$69.5M
Cap. Flow %
8.01%
Top 10 Hldgs %
48.78%
Holding
127
New
31
Increased
30
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$14.1M
2
APGE icon
Apogee Therapeutics
APGE
+$11.9M
3
CLYM
Climb Bio
CLYM
+$11.1M
4
ACLX
Arcellx
ACLX
+$8.7M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$8.33M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.7M
2
ABSI icon
Absci
ABSI
+$5.82M
3
CYTK icon
Cytokinetics
CYTK
+$5.61M
4
KRYS icon
Krystal Biotech
KRYS
+$4.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 65.41%
2 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
76
DELISTED
Kezar Life Sciences
KZR
$1.06M 0.12%
176,178
– –
TECX
77
Tectonic Therapeutic
TECX
$605M
$961K 0.11%
58,331
-2
-0% -$32
PBYI icon
78
Puma Biotechnology
PBYI
$422M
$815K 0.09%
+250,000
New +$1.1M
ZURA icon
79
Zura Bio
ZURA
$500M
$782K 0.09%
223,335
-226,674
-50% -$924K
ALXO icon
80
CALL
ALX Oncology
ALXO
$258M
$603K 0.07%
+100,000
New +$1.23M
INSM icon
81
PUT
Insmed
INSM
$23.2B
$583K 0.07%
+8,700
New +$337K
AVTX icon
82
Avalo Therapeutics
AVTX
$957M
$561K 0.06%
45,000
+35,000
+350% +$454K
QTTB icon
83
Q32 Bio
QTTB
$346M
$499K 0.06%
27,777
– –
IMTXW
84
DELISTED
Immatics N.V. Warrants
IMTXW
$485K 0.06%
187,204
– –
MTVA
85
MetaVia Inc
MTVA
$8.68M
$432K 0.05%
+8,111
New +$347K
PMN icon
86
ProMIS Neurosciences
PMN
$135M
$399K 0.05%
10,638
– –
JBIO
87
Jade Biosciences
JBIO
$1.2B
$332K 0.04%
+5,714
New +$3.79M
ORKA
88
Oruka Therapeutics
ORKA
$5.53B
$278K 0.03%
+6,040
New +$241K
RAPT
89
DELISTED
RAPT Therapeutics
RAPT
$229K 0.03%
+9,375
New +$433K
PASG icon
90
Passage Bio
PASG
$15.5M
$210K 0.02%
13,213
– –
GNLX icon
91
Genelux
GNLX
$131M
$195K 0.02%
+100,000
New +$340K
RCKTW icon
92
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$4.52K ﹤0.01%
75,000
– –
IOVA icon
93
Iovance Biotherapeutics
IOVA
$2.24B
$802 ﹤0.01%
+100
New +$1.07K
ABSI icon
94
Absci
ABSI
$1.38B
– –
-1,025,000
Closed -$5.82M
AKRO
95
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-75,000
Closed -$1.89M
ALNY icon
96
CALL
Alnylam Pharmaceuticals
ALNY
$36.4B
– –
-40,000
Closed -$5.98M
ANVS icon
97
PUT
Annovis Bio
ANVS
$71.9M
– –
-72,900
Closed -$868K
APLS
98
DELISTED
Apellis Pharmaceuticals
APLS
– –
-165,000
Closed -$9.7M
BBIO icon
99
CALL
BridgeBio Pharma
BBIO
$15.8B
– –
-250,000
Closed -$7.73M
BSX icon
100
Boston Scientific
BSX
$65.1B
– –
-25,000
Closed -$1.71M
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Affinity Asset Advisors held 127 positions worth $868M, up 7.4% from $808M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Affinity Asset Advisors deployed $69.5M of net new capital in Q2 2024, opening 31 new positions and adding to 30 existing holdings. Its largest new stake was Climb Bio: 1,670,661 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 71% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.42M trimmed.

  • Affinity Asset Advisors's largest Q2 2024 buy was Climb Bio: 1,670,661 shares worth $11.9M.
  • Affinity Asset Advisors added most to Alkermes in Q2 2024, an estimated $14.1M increase.
  • Affinity Asset Advisors's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $4.42M.
  • Affinity Asset Advisors fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $9.7M.
  • Affinity Asset Advisors's ten largest holdings make up 49% of its $868M portfolio in Q2 2024.
  • Affinity Asset Advisors opened 31 new positions and closed 29 in Q2 2024.
  • Affinity Asset Advisors's portfolio value rose 7.4% quarter-over-quarter to $868M.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.